Exagen, Inc. XGN
NASDAQ · United States · Health Services
$8.02-0.11 (-1.35%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Exagen now carries a modestly higher implied fair value, with the target shifting from about US$8.67 to roughly US$9.71 per share. Analysts link this change to a mix of optimism around the AVISE CTD autoimmune testing portfolio and caution around execution and valuation, as they assess how the current business can support the updated target. Read on to see what this may mean for you as an investor and how to track the evolving Exagen narrative from here. Analyst Price Targets don't always...
Moby summary of Exagen Inc.'s Q2 2026 earnings call
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Exagen Inc (XGN) reports record Q2 revenue of $19.9 million, nearly achieving adjusted EBITDA breakeven, and raises full-year guidance.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.